Semaglutide is becoming one of the most impressive drugs in modern medicine (GLP-1 antagonists) A new analysis of 17,604 people with cardiovascular disease and overweight or obesity found that it reduced the inflammatory marker hsCRP by 38%. But more interesting: The effect began within weeks, before substantial weight loss had occurred, and was even observed in people who did not (!) lose weight. Patients with the highest inflammation had a 2–4× greater risk of cardiovascular events and death, while semaglutide reduced cardiovascular risk across all inflammation levels. Seriously, this medication is a miracle. Presumably, it should soon be recommended to almost everyone.